Y02001 Recombinant human IL2
发表时间:2023-09-15Y02001 Recombinant human IL2
白细胞介素-2 (IL-2)是一种15.5 kda可变糖基化的球状蛋白,最初被描述为T细胞生长因子。IL-2主要由抗原刺激后的CD4+ T淋巴细胞(幼稚、记忆和辅助T淋巴细胞[Th] 1)、小肠2型和3型先天淋巴细胞产生,少量由活化的CD8+ T细胞、B细胞和其他先天免疫实体如自然杀伤(NK)和NKT淋巴细胞、树突状细胞(dc)、单核细胞或肥大细胞产生。IL-2一旦被分泌,就会被含有其受体IL-2R的邻近细胞以自分泌/旁分泌的方式消耗。后者由多达三个亚基的杂络合物组成:α, β和γ,也分别称为CD25, CD122和CD132。γ亚基在大多数造血细胞中普遍表达。它也被称为“公共”链(标记为“γ - c”),因为它与IL-4, -7, -9, -15和-21的受体共享。IL-2与IL-2R结合激活JAK1/3。反过来,这些激酶激活pi3k /PIP3/AKT/mTOR/p70S6K和Ras/Raf/ map2k1 /ERK1/2信号级联并磷酸化STAT5,以调节参与蛋白质合成、自噬、细胞代谢、存活、增殖和分化的多种下游调节因子的活性和新生表达。
IL-2是一种多效性细胞因子,根据靶细胞的不同具有免疫刺激或免疫抑制活性。其对非造血细胞和先天免疫细胞的影响仍不清楚。最重要的是,IL-2作为T细胞发育和稳态的一种成熟的调节因子而突出。
图 IL-2-IL-2R 信号传导和T细胞活性的调节
SDS-PAGE
Recombinant Human IL-2 SDS-PAGE under reducing (R) & Non-reducing conditions. The gel was stained with Recombinant Human IL-2 SDS-PAGE.
Bioactivity
Human IL-2 Protein (Cat. No. Y02001) stimulates
proliferation of CTLL-2 cells. The specific activity of
Human IL-2 Protein (Cat. No. Y02001) is ≥1 x 107 IU/mg.
Bioactivity

Highly consistent bioactivity between different production
batches of Human IL-2 Protein (Cat. No. Y02001).
参考文献
Pol JG, et al. 2020. J Exp Med. 217(1):e20191247.
Ross SH, Cantrell DA. 2018. Annu Rev Immunol. 36:411-433.
其他相关产品:
名称 |
种属 |
货号 |
规格 |
纯度 |
内毒素(EU/mg) |
表达系统 |
Transferrin |
Human |
Y04501 |
1g |
≥99% |
<0.5 |
真核 |
IL2 |
Human |
Y02001 |
100ug/1mg |
≥99% |
<0.5 |
真核 |
FetuinA |
Human |
Y07501 |
1g |
≥95% |
<0.5 |
真核 |
FetuinA |
Bovine |
Y07511 |
1g |
≥95% |
<0.5 |
真核 |
Fibronectin |
Human |
Y01301 |
1mg |
≥95% |
<0.5 |
真核 |
Vitronectin |
Human |
Y04801 |
50ug/1mg |
≥90% |
<10 |
真核 |
LR3 IGF1 |
Human |
Y03101 |
1mg |
≥95% |
<10 |
真核 |
BDNF |
Human |
Y00201 |
50ug/1mg |
≥95% |
<10 |
真核 |
EGF |
Human |
Y00801 |
50ug/1mg |
≥95% |
<10 |
真核 |
bFGF |
Human |
Y00301 |
50ug/1mg |
≥95% |
<10 |
真核 |
FGF4 |
Human |
Y00901 |
50ug/1mg |
≥95% |
<10 |
真核 |
FGF7 |
Human |
Y05901 |
50ug/1mg |
≥95% |
<10 |
真核 |
FGF9 |
Human |
Y01001 |
50ug/1mg |
≥90% |
<10 |
真核 |
FLT-3L |
Human |
Y01201 |
50ug/1mg |
≥95% |
<10 |
真核 |
GM-CSF |
Human |
Y01501 |
50ug/1mg |
≥95% |
<10 |
真核 |
HGF |
Human |
Y01701 |
50ug/1mg |
≥90% |
<10 |
真核 |
IFNγ |
Human |
Y01801 |
50ug/1mg |
≥95% |
<10 |
真核 |
IL-1a |
Human |
Y01901 |
50ug/1mg |
≥95% |
<10 |
真核 |
IL-4 |
Human |
Y02201 |
50ug/1mg |
≥95% |
<10 |
真核 |
IL6 |
Human |
Y02301 |
50ug/1mg |
≥95% |
<10 |
真核 |
IL7 |
Human |
Y02401 |
50ug/1mg |
≥90% |
<10 |
真核 |
IL15 |
Human |
Y02703 |
50ug/1mg |
≥90% |
<10 |
真核 |
IL18 |
Human |
Y02801 |
50ug/1mg |
≥90% |
<10 |
真核 |
IL21 |
Human |
Y02901 |
50ug/1mg |
≥95% |
<10 |
真核 |
NRG1 |
Human |
Y01601 |
50ug/1mg |
≥95% |
<10 |
真核 |
Noggin |
Human |
Y03301 |
50ug/1mg |
≥95% |
<10 |
真核 |
OSM |
Human |
Y05101 |
50ug/1mg |
≥95% |
<10 |
真核 |
R-Spondin1 |
Human |
Y03501 |
50ug/1mg |
≥95% |
<10 |
真核 |
SCF |
Human |
Y03801 |
50ug/1mg |
≥95% |
<10 |
真核 |
TGFβ1 |
Human |
Y04201 |
50ug/1mg |
≥95% |
<10 |
真核 |
TGFβ2 |
Human |
Y07801 |
50ug/1mg |
≥95% |
<10 |
真核 |
TGFβ3 |
Human |
Y07901 |
50ug/1mg |
≥95% |
<10 |
真核 |
TNFα |
Human |
Y04401 |
50ug/1mg |
≥95% |
<10 |
真核 |
VEGF165 |
Human |
Y04701 |
50ug/1mg |
≥95% |
<10 |
真核 |
CD3 mAb |
Human |
C00404 |
1mg |
≥95% |
<10 |
真核 |
CD28 mAb |
Human |
C02302 |
1mg |
≥95% |
<10 |
真核 |